Stock Financial Ratios, Dividends, Split History

HRTX / Heron Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price38.75
Volume469,400.00
Market Cap ($M)2,777.31
Enterprise Value ($M)2,723.54
Book Value ($M)92.21
Book Value / Share1.28
Price / Book30.12
NCAV ($M)85.39
NCAV / Share1.19
Price / NCAV32.44
Share Statistics
Common Stock Shares Outstanding 64,609
Common Shares Outstanding 64,648,383
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.51
Return on Assets (ROA)-2.93
Return on Equity (ROE)9.29
Balance Sheet (mrq) ($M)
Assets183.38
Liabilities91.18
Quick Ratio1.72
Current Ratio1.94
Income Statement (mra) ($M)
Sales Revenue Goods Net30,767,000.00
Operating Income-194.56
Net Income-197.48
Earnings Per Share Basic And Diluted-3.65
Cash Flow Statement (mra) ($M)
Cash From Operations-170.30
Cash from Investing7.74
Cash from Financing7.74
Identifiers and Descriptors
CUSIP427746102
Central Index Key (CIK)818033
Related CUSIPS
427746902 427746952

Split History

Stock splits are used by Heron Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Liquidia To File IPO - What Investors Need To Know

2018-07-02 seekingalpha
Liquidia Technologies (LQDA), has filed the necessary paperwork with the SEC to make an initial public offering. The biopharma company is seeking to raise at least $57 million and will trade on the NASDAQ Capital Market. Jefferies and Cowen will run the book on the IPO. (124-0)

Heron Therapeutics: What The Topline Results For The 2 Phase 2B Trials Of HTX-011 Foretell

2018-06-29 seekingalpha
Company concurrently focuses on servicing two market segments, cancer-induced nausea and vomiting ("CINV") and pain control. Approved molecules (Cinvanti and Sustol) to provide the cash to support the developing drugs. (18-0)

Your Daily Pharma Scoop: Heron Spikes, Ironwood Pharma Moves Ahead, Mesoblast Positive

2018-06-27 seekingalpha
The Daily Scoop is going to turn one year soon. Thank you for reading, commenting, and supporting our efforts. Please go to the end of this article to read an important announcement. (148-2)

Heron Therapeutics: Update After HTX-011 Nerve Block Results

2018-06-26 seekingalpha
HTX-011 alone or in combination with ropivacaine significantly reduced post-surgical pain compared to placebo and also to bupivacaine. (18-0)

Marketplace Blog Spotlight: June

2018-06-25 seekingalpha
Here, we highlight several Marketplace authors' blog posts from June, which contain some interesting investing ideas and strategies. (51-1)

CUSIP: 427746102